Evaluation of the added value of Brain Natriuretic Peptide to a validated mortality risk-prediction model in older people using a standardised international clinical assessment tool

TitleEvaluation of the added value of Brain Natriuretic Peptide to a validated mortality risk-prediction model in older people using a standardised international clinical assessment tool
Publication TypeJournal Article
Year of Publication2022
AuthorsPickering J.W, Scrase R., Troughton R., Jamieson H.A
JournalPLoS ONE
Volume17
Issue11 November
Paginatione0277850
Keywords*brain natriuretic peptide/ec [Endogenous Compound], *clinical assessment tool, *clinical evaluation, *international resident assessment instrument homecare, *mortality risk, *prediction, *risk model, Aged, area under the curve, article, biological marker/ec [Endogenous Compound], body mass, cerebrovascular accident, cohort analysis, congestive heart failure/cn [Congenital Disorder], controlled study, daily life activity, demographics, diagnostic test accuracy study, dyspnea, Exercise, fatigue, Female, health care personnel, Human, length of stay, major clinical study, Male, malignant neoplasm, New Zealand, outcome assessment, oxygen therapy, parkinson disease, proof of concept, receiver operating characteristic, skin ulcer, statistical analysis, very elderly
Abstract

The ability to accurately predict the one-year survival of older adults is challenging for clinicians as they endeavour to provide the most appropriate care. Standardised clinical needs assessments are routine in many countries and some enable application of mortality prediction models. The added value of blood biomarkers to these models is largely unknown. We undertook a proof of concept study to assess if adding biomarkers to needs assessments is of value. Assessment of the incremental value of a blood biomarker, Brain Naturetic Peptide (BNP), to a one year mortality risk prediction model, RiskOP, previously developed from data from the international interRAI-HomeCare (interRAI-HC) needs assessment. Participants were aged >=65 years and had completed an interRAI-HC assessment between 1 January 2013 and 21 August 2021 in Canterbury, New Zealand. Inclusion criteria was a BNP test within 90 days of the date of interRAI-HC assessment. The primary outcome was one-year mortality. Incremental value was assessed by change in Area Under the Receiver Operating Characteristic Curve (AUC) and Brier Skill, and the calibration of the final model. Of 14,713 individuals with an interRAI-HC assessment 1,537 had a BNP within 90 days preceding the assessment and all data necessary for RiskOP. 553 (36.0%) died within 1-year. The mean age was 82.6 years. Adding BNP improved the overall AUC by 0.015 (95% CI:0.004 to 0.028) and improved predictability by 1.9% (0.26% to 3.4%). In those with no Congestive Heart Failure the improvements were 0.029 (0.004 to 0.057) and 4.0% (0.68% to 7.6%). Adding a biomarker to a risk model based on standardised needs assessment of older people improved prediction of 1-year mortality. BNP added value to a risk prediction model based on the interRAI-HC assessment in those patients without a diagnosis of congestive heart failure.Copyright © 2022 Pickering et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DOI10.1371/journal.pone.0277850
Short TitlePLoS ONE